This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -50% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 50% and 0.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Reports Q1 Loss
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 2.86% and 0%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will HealthEquity (HQY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
HealthEquity (HQY) New Tie Up to Meet Clients' Healthcare Needs
by Zacks Equity Research
HealthEquity's (HQY) latest collaboration is expected to enhance digital transformation with Microsoft Azure and build better experiences for customers and employees.
HealthEquity (HQY) Beats on Q4 Earnings, Margins Rise
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, alongside recording robust performances in all its segments, in the fourth quarter of fiscal 2023.
HealthEquity (HQY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 8.82% and 1.92%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
HealthEquity (HQY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cano Health, Inc. (CANO) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cano Health, Inc. (CANO) delivered earnings and revenue surprises of 280% and 3.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
Humana (HUM) Subsidiary Wins $70.8B DoD East Region Contract
by Zacks Equity Research
The latest award marks Humana's (HUM) military subsidiary's sixth TRICARE contract win.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.
Here's What You Should Know From Centene's (CNC) 2023 Outlook
by Zacks Equity Research
Centene's (CNC) board boosts its share buyback program with a new $2-billion fund.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors are optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Stryker's (SYK) Citrefix to Boost Foot and Ankle Surgeries
by Zacks Equity Research
Stryker's (SYK) newly-launched Citrefix will help customers avoid chronic inflammation using Citregen. Its pull-out strength is greatly increased compared to other suture anchors.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Progyny
by Zacks Equity Research
Medpace, HealthEquity and Progyny have been highlighted in this Industry Outlook article.
3 Medical Services Stocks to Buy Amid Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and PGNY are set to gain the most. However, staffing shortages may disrupt the trend.
How Much Upside is Left in HealthEquity (HQY)? Wall Street Analysts Think 30%
by Zacks Equity Research
The mean of analysts' price targets for HealthEquity (HQY) points to a 29.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.